Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial

What Was Tested

This randomized controlled trial paper looks at Carnosine.

To evaluate the cardiac function, echocardiography was performed upon admission to the hospital and at 9 months post-AMI.

Why It Was Studied

Polaprezinc is clinically used for the treatment of gastric ulcers.

It induces the mobilization of mesenchymal stem cells and the mRNA expression of insulin-like growth factor-1 in vascular endothelial cells in order to protect injured gastric tissue or skin.

Who Took Part

The abstract describes 50 patients taking part.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

The current study population included 50 patients with primary acute myocardial infarction (AMI).

After percutaneous coronary intervention, the subjects were randomly divided into 2 groups, namely, the nonpolaprezinc and polaprezinc groups.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Carnosine study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Peripheral blood and urinary samples were collected in a specific time to analyze zinc concentration, cardiac enzymes, and the levels of the inflammation marker interleukin-6.

What Was Measured

The subject headings attached to it are Anti-Inflammatory Agents, Biomarkers, Cardiovascular Agents, Carnosine, Electrocardiography, Myocardial Infarction and Organometallic Compounds.

What This Means in Plain Language

The paper is a randomized study of Carnosine in 50 patients.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Medicine), a journal based in United States.

More context: the Carnosine compound page, all human trials.